"The recent release of Librela, touted as a "miracle drug" for canine osteoarthritis, has deeply impacted thousands of pet owners and their beloved companions internationally since 2021."  I am quoting this from Sam B. who is a veterinary professional with over a decade of experience.  Sam has witnessed firsthand the devastating consequences of the drug Librela, which is used to control pain from arthritis in dogs. Solensia is the same drug used to control pain from osteoarthritis in cats. Despite its promise of relief from arthritis pain, Librela & Solensia have resulted in thousands of adverse reactions, leaving dogs & cats in agony and their owners desperate for answers. It is imperative that action is taken to address this urgent issue.

The continued availability and promotion of Librela & Solensia pose a grave threat to the well-being of countless dogs and cats. With each passing day, more dogs and cats are subjected to unnecessary suffering and even death as a result of severe adverse reactions to these drugs. The lack of accountability from the manufacturer, Zoetis, exacerbates the problem, leaving pet owners with broken hearts, mounting medical bills, and unanswered questions. If left unchecked, the widespread use of Librela and Solensia could lead to irreversible harm to countless canine and feline companions and erode trust in the veterinary pharmaceutical industry and Zoetis.

The urgency of this situation cannot be overstated. Every moment that Librela and Solensia remain on the market without further investigation and evaluation is a moment that puts more dogs and cats at risk. Immediate action is needed to recall Librela & Solensia and subject it to thorough testing to determine its safety and efficacy. Zoetis has failed to provide crucial information on how long Librela and Solensia lasts after injection, its complete metabolic process, and the management of adverse reactions, leaving pet owners and veterinarians in the dark. While some dogs and cats may experience success with Librela and Solensia, the thousands of dogs and cats suffering from adverse reactions cannot be ignored. Zoetis should enhance the clarity of its product information regarding Librela and Solensia, specifying suitable candidates for its use. This is particularly important given the drug's mechanism as a monoclonal antibody that targets the nerve growth factor (NGF). Together we must demand accountability from Zoetis and prioritize the health and well-being of our beloved canine & feline companions.